Xeris Biopharma Holdings Q1 EPS $(0.14) Misses $(0.12) Estimate, Sales $40.64M Miss $41.81M Estimate
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma Holdings (NASDAQ:XERS) reported Q1 EPS of $(0.14), missing the $(0.12) estimate, and sales of $40.64M, missing the $41.81M estimate. This represents a 16.67% decrease in EPS and a 22.42% increase in sales year-over-year.
May 09, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Xeris Biopharma Holdings reported a Q1 EPS of $(0.14), missing estimates, and sales of $40.64M, also below expectations.
Missing both EPS and sales estimates can negatively impact investor sentiment and stock price in the short term. The decrease in EPS year-over-year further compounds concerns, despite the increase in sales, indicating potential issues with profitability or cost management.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100